Overview

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease. Eligibility required neurological examination by the study doctor and assessment of the patient's pain. Eligible participants were randomized to receive blinded study medication for a total of 12 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Ranolazine